Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In The News: Tracking The Latest Industry Personnel Moves

Executive Summary

President & CEO

You may also be interested in...

Merck Names Ken Frazier President

The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.

Business In Brief

CHMP recommends approval of Nycomed's Daxas: Nycomed's chronic obstructive pulmonary disorder therapy Daxas (roflumilast) received a recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use, the company announced April 23. Daxas is recommended for maintenance treatment of severe COPD (FEV1 post-bronchodilator less than 50 percent predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as an add-on to bronchodilator treatment. CHMP is all but tantamount to full EU approval and Nycomed expects to launch the drug later this year. If Daxas gains marketing authorization there, it would be the first in a new class of oral agents for COPD. The drug is not faring as well in the U.S., however. On April 7, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended against approval of Daxas (1"The Pink Sheet" DAILY, April 7, 2010)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts